Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

Patent metadata

Field	Value
Publication number	US-10500207-B2
Application number	US-201514930442-A
Country	US
Kind code	B2
Filing date	Nov 2, 2015
Priority date	Apr 16, 2010
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

First claim

We claim:

1. A method of inhibiting Aß1-42 aggregation, Tau aggregation and/or alpha-synuclein aggregation comprising:
administering to a subject an effective amount of a compound having the formula (I):
A-L 1 -B  (I)

or a stereoisomer, racemic mixture, or pharmaceutically acceptable salts thereof;
wherein A is:

L 1 is:

B is:

wherein
R 2 and R 3 are each independently selected from the group consisting of hydrogen, halogen, —CN, —CF 3 , —CONR 30 R 31 , —N(R 30 )—C(O)—R 31 , a —O—C 1 -C 6 alkyl, and C 5 -C 10 heterocycloalkyl, or wherein R 2 and R 3 taken together form a 5- or 6-membered ring containing carbon atoms and optionally one or two heteroatoms selected from O, S, or N;
R 1 is hydrogen or halogen;
R a is hydrogen or C 1 -C 6 alkyl;
for each occurrence, R b is independently selected from the group consisting of: hydrogen, halogen, CN, CONR 30 R 31 , or C 1 -C 6 alkyl;
for each occurrence, R 30 , R 31 , and R 20 are each independently selected from the group consisting of hydrogen, or C 1 -C 6 alkyl;
Y is CH or N; and
z is 1 or 2, thereby inhibiting Aß1-42 aggregation, Tau aggregation and/or alpha-synuclein aggregation.

2. The method of claim 1 , wherein Y is N.

3. The method of claim 1 , wherein Y is CH.

4. The method of claim 1 , wherein z is 1.

5. The method of claim 1 , wherein z is 2.

6. The method of claim 1 , wherein Y is N and z is 2.

7. The method of claim 1 ,
wherein
B is:

8. The method of claim 7 ,
wherein
B is:

9. The method of claim 8 ,
wherein A is:

and
B is:

10. The method of claim 9 , wherein the compound is:

11. The method of claim 9 , wherein the compound is:

12. The method of claim 1 ,
wherein
B is:

13. The method of claim 1 , wherein the compound is selected from:

14. The method of claim 1 , further comprising administering a cholinesterase inhibitor (ChEI).

15. The method of claim 1 , further comprising administering pirenzepin, 3-amino-1-propanesulfonic acid (3APS), 1,3-propanedisulfonate (1,3PDS), α-secretase activator, β-secretase inhibitor, γ-secretase inhibitor, tau protein, pyroglutamated amyloid beta 3-42, M1 agonists, neurotransmitters, β-sheet breakers, tacrine, rivastigmine, donepezil, galantamine, niacin and/or memantine.

16. The method of claim 1 , wherein the subject suffers from Alzheimer's disease (AD), Lewy body dementia (LBD), Down's syndrome, mild cognitive impairment (MCI), Parkinson's disease, glaucoma, or macular degeneration.

17. The method of claim 16 , wherein the macular degeneration is s age-related macular degeneration (AMD).

18. A method of retaining or increasing cognitive memory capacity in a subject suffering from memory impairment comprising administering to a subject in need of such treatment an effective amount of a compound having the formula (I):
A-L 1 -B  (I)

or a stereoisomer, racemic mixture, or pharmaceutically acceptable salt thereof;
wherein A is:

L 1 is:

B is:

wherein
R 2 and R 3 are each independently selected from the group consisting of hydrogen, halogen, —CN, —CF 3 , —CONR 30 R 31 , —N(R 30 )—C(O)—R 31 , a —O—C 1 -C 6 alkyl, and C 5 -C 10 heterocycloalkyl, or wherein R 2 and R 3 taken together form a 5- or 6-membered ring containing carbon atoms and optionally one or two heteroatoms selected from O, S, or N;
R 1 is hydrogen or halogen;
R a is hydrogen or C 1 -C 6 alkyl;
for each occurrence, R b is independently selected from the group consisting of: hydrogen, halogen, CN, CONR 30 R 31 , or C 1 -C 6 alkyl;
for each occurrence, R 30 , R 31 , and R 20 are each independently selected from the group consisting of hydrogen, or C 1 -C 6 alkyl;
Y is CH or N; and
z is 1 or 2.

Assignees

• Ac Immune Sa

Inventors

• Kroth Heiko
• Hamel Cotinica
• Benderitter Pascal
• Froestl Wolfgang
• Sreenivasachary Nampally
• Muhs Andreas

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P27/12

  for cataracts · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61P27/02

  Ophthalmic agents · CPC title